| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Xcyte Therapies, Inc., Seattle, WA 98104;
Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY 10032;
Laboratoire de Thérapeutique Immuno-Moléculaire, Institut National de la Santé et de la Recherche Médicale Unité 645/EA2284, Institut Fédératif de Recherche 133, Etablissement Français du Sang Bourgogne/Franche-Comté, Besançon, France;
Trubion Pharmaceuticals, Inc., Seattle, WA 98121; and
¶
Center for Hematology and Malignancies, Oregon Health and Science University, Portland, OR 97239
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of leukemic B cells concomitant with immunological abnormalities and depressed immune responses. The T cell abnormalities found in CLL patients are thought to increase the risk of infection and hamper immune recognition and elimination of leukemic cells. We evaluated whether providing signals through CD3 and CD28 would correct some of these T cell defects. PBMC were incubated with anti-CD3 and anti-CD28 mAbs conjugated to superparamagnetic beads for 12–14 days. This resulted in a 1400-fold increase in T cell numbers. Activated T cells expressed high levels of CD25, CD54, CD137, and CD154, and produced IFN-
, TNF-
, and GM-CSF. The mean T cell composition of cultures increased from 
6% to >90% and leukemic B cells decreased from a mean of 85% to 0.1% or less. Leukemic B cells up-regulated expression of CD54, CD80, CD86, and CD95. Receptor up-regulation required direct cell contact with the activated T cells and could be blocked with anti-CD154 mAb, suggesting that the CD40-CD40L pathway helped mediate these effects. Poor T cell responses to allostimulation were corrected by the activation and expansion process. The skewing in the TCR repertoire returned to normal, or near normal following the culture process in eight of nine patients with abnormal TCR repertoires. Activated T cells had potent in vitro antileukemic effects in contrast to nonactivated T cells. Based upon these findings, a clinical trial has been initiated to test the potential therapeutic effects of T cells activated using this approach in patients with CLL.
This article has been cited by other articles:
|
|
 |
|
  D. J. Powell Jr and B. L. Levine Adoptive T-cell therapy for malignant disorders Haematologica, October 1, 2008; 93(10): 1452 - 1456. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells J. Immunol., July 1, 2008; 181(1): 808 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prieto, M. Sanchez, E. Perucha, and M. Alvarez-Mon Effect of CD3/CD28 Bead-Activated T Cells on Leukemic B Cells in Chronic Lymphocytic Leukemia J. Immunol., August 15, 2005; 175(4): 2042 - 2043. [Full Text] [PDF]
|
|
|
|
|
|
P. Patten, S. Devereux, A. Buggins, M. Bonyhadi, M. Frohlich, and R. J. Berenson Effect of CD3/CD28 Bead-Activated and Expanded T Cells on Leukemic B Cells in Chronic Lymphocytic Leukemia J. Immunol., June 1, 2005; 174(11): 6562 - 6563. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
